SillaJen Inc (215600.KQ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · South Korea · ISIN KR7215600008
SillaJen Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 3.93 bn KRW | 9.23 bn KRW |
| Gross profit | 727.29 m KRW | 5.29 bn KRW |
| Operating income | -28.12 bn KRW | -26.32 bn KRW |
| EBIT | -24.63 bn KRW | -22.97 bn KRW |
| Net income | -26.53 bn KRW | -24.19 bn KRW |
| Diluted EPS – continuing operations | -193.21 KRW | -175.12 KRW |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SillaJen Inc
SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. The company also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. In addition, it operates in biotechnology research industry. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
More stocks
- OE Solutions Co. Ltd (138080.KQ)
- ANGEL ROBOTICS Co., Ltd. (455900.KQ)
- Mastersystem Infotama Tbk. (MSTI.JK)
- Sinphar Pharmaceutical Co Ltd (1734.TW)
- Brogent Technologies (5263.TWO)
- Keros Therapeutics, Inc. (KROS)
- MPC Muenchmeyer Petersen Capital (MPCK.DE)
- TREDEGAR CORP (TG)
- Chlitina Holding Ltd (4137.TW)
- Aumann (AAG.DE)
- Ta Chia Yung Ho Machine Industry Co Ltd (2221.TWO)
- Streamwide (ALSTW.PA)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.